MEDIAN Technologies, Microsoft Collaborate
News Jul 01, 2016
MEDIAN Technologies and Microsoft have announced a joint global initiative in the rapidly growing Precision Medicine market to develop new cancer detection, diagnosis and monitoring methods using Big Data analytics. As part of the initiative, MEDIAN Technologies will collaborate with Microsoft to install its groundbreaking imaging biomarker phenotyping system (IBIOPSY™) on the Microsoft Azure cloud computing platform.
On Azure, IBIOPSY™ will provide capabilities for processing and analyzing medical images, extracting biomarkers of disease in real time for cancer diagnosis and treatment purposes. “Precision Medicine is about to revolutionize how diagnostic and biological data is used to pinpoint and deliver care that is preventive, targeted and effective” said Fredrik Brag Chief Executive Officer at MEDIAN Technologies.
“Extracting biomarkers of disease from medical images is at the core of the Precision Medicine effort. Big Data computing and analytics will allow efficient processing and analysis of imaging biomarkers which is essential for early detection of cancer and monitoring of new targeted cancer treatments. Our collaboration with Microsoft will allow us to deliver these solutions into routine clinical practice on a global scale on the Azure Cloud Computing platform.”
“Microsoft Innovation teams are committed to providing their technical expertise to health professionals who use medical images in their daily routine. We are proud to collaborate with MEDIAN on the IBIOPSY™ project and to bring innovative technologies at the service of cancer research”, said Bernard Our ghanlian, Chief Technology & Security Officer at Microsoft France.
“Indeed, we are, more than ever committed to addressing the biggest challenges in cancer detection, diagnosis and monitoring, by offering access to the latest and most innovative technologies. By taking advantage of the powerful Microsoft Azure cloud platform, IBIOPSY™ will provide faster imaging and health data analysis and will accelerate the discovery and delivery of new biomarkers for cancer diagnosis and treatment monitoring.”
IBIOPSY™ will eventually be made available to medical facilities and physicians in the US, Europe, and Asia to meet the image processing and data analytics needs created by the next generation of personalized cancer therapies and the explosive growth in medical imaging data. MEDIAN Technologies and Microsoft will work together to help medical centers take advantage of the Azure capabilities.
Also MEDIAN Technologies and Microsoft collaboration will focus on the development of novel predictive analytics methods based on machine learning and encryption capabilities that will be available on Azure.
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Understanding the Process of Cell DivisionNews
Using multiple techniques such as structural modelling, X-ray scattering, X-ray crystallography and electron microscopy, scientists have found that the Spc110 protein provides a greater function in mitosis originally believed. This information could help understand the process in human cells and the abnormalities that occur in cancer.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018